Cabozantinib Plus Atezolizumab Active in mCRPC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 19, 2020
Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute

Neeraj Agarwal, MD

The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with high-risk clinical features, according to cohort findings of the phase Ib COSMIC-021 trial (NCT03170960) that were presented at the 2020 Genitourinary Cancers Symposium.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication